Research programme: peptide therapeutics - SynVax
Alternative Names: NOP receptor agonists - SynVax; Syn 1020Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator SynVax Pharmaceuticals
- Class
- Mechanism of Action Diuretics; Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Bacterial infections; Heart failure; Major depressive disorder; Mycoses; Oedema; Pain; Viral infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in USA